Eric Mayer has been the President and Chief Executive Officer of New Day Diagnostics since 2023, following the merger of New Day Diagnostics and EDP Biotech, where he had served as Chief Executive Officer since 2015. Eric previously served as Vice President of Business Development at EDP Biotech, overseeing various aspects of product development, intellectual property, and forming alliances with manufacturing
partners.

Earlier in his career, Eric Mayer directed business development at BioPet Vet Lab, resulting in the market launch, distribution, and subsequent revenue growth of BioPet’s primary genetic product. His experience includes nearly a decade of start-up biotech involvement with diagnostic firms such as AAD, Inc., and research companies such as Metabolon, Inc. and Cirrus Pharmaceuticals.

Eric received his B.S. in Biochemistry from UNC Chapel Hill, and his M.S. in Microbial Biotechnology and M.B.A. from North Carolina State University.

Greg Hamilton has over 25 years of management experience in molecular diagnostics, manufacturing, and professional services industries. Greg currently serves as CEO and Board member of io9, Inc. Prior to io9, he served as CEO and Executive Board member of Epigenomics AG, Board member of Eracal Therapeutics, CEO and Board member of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc., and Vice President of Operations at Hologic Inc.

Greg has been responsible for multiple FDA-cleared products, including the first-ever FDA-approved liquid biopsy test, a Human Papillomavirus (HPV) High-Risk Screening assay, and the first-ever cleared HPV genotyping assay.

Greg received his MBA from the University of Chicago and his B.S. in Finance from Purdue University.

Greg Wujek has more than 30 years of biopharma experience in roles of increasing responsibility. Currently, he serves as the Chief Commercial Officer at Actum Pharma. Previously, he led the Life Science Industry Consultants at SAS and recently held the role of Chief Commercial Officer at CCB. Previously, Greg served as Chief Executive Officer of Castle Creek Pharmaceuticals, where he led the purchase of Fibrocell Science. Prior to joining Castle Creek, he managed and developed successful strategies for Zimmer Biomet/Biologics Unit, overseeing the launch of their first prescription injectable product, Gel-One®.

Earlier in his career, Greg also led the build-out of Savient’s biologics arm, taking responsibility for sales, market access, and operations in support of EUFLEXXA®, the company’s first biologic launch. Prior to Savient, Greg was also responsible for managing the team that successfully launched ALTOPREV® and FORTAMET® at Andrx Laboratories. Greg began his career at Forest Laboratories, where he quickly advanced and took responsibility for building out the Market Access department in support of the company’s first blockbuster, TIAZAC®.

Greg graduated from Illinois State University with a B.S. in Political Science.

Jason Baumgartner is a seasoned leader in healthcare technology and consulting, currently serving as the Founder and CEO of Thrivr Health. Thrivr Health is a cancer care navigation platform that partners with providers and insurers to support patients throughout their cancer journey. Since its inception in November 2023, Jason has driven Thrivr Health's mission to improve the health and well-being of cancer patients by providing them with a trusted care navigation partner.

Prior to founding Thrivr Health, Jason was the Founder and CEO of BEKHealth, a clinical research technology company. At BEKHealth, he provided advanced EMR data processing, feasibility, and patient recruiting solutions for research organizations and pharmaceutical companies, significantly contributing to the success of clinical trials and the accelerated development of new drugs and therapies.

Jason' s extensive career also includes his role as Vice President of Customer Success at SHYFT Analytics. Before SHYFT Analytics, he served as a Principal at Quintiles, now part of IQVIA, where he provided strategic consulting services to biopharma clients. Earlier in his career, Jason held the position of Practice Executive in the Biopharma Consulting Practice at Campbell Alliance, where he specialized in biopharmaceutical consulting.

Jason holds an MBA from Duke University's Fuqua School of Business.

Kenneth A. Sorensen, Ph.D. is a noted biotechnology entrepreneur, investor, financier, and research scientist. Ken combines a data-driven analytic approach with high-quality research results and talented business development team members to achieve his long-term vision of unlocking new areas of biotechnology innovation. Ken has successfully raised more than $1 billion of capital and transactions to enable new biotechnology companies to move from scientific concept to commercialized products.

Ken founded Array Capital Management LLC in 2000, a life sciences merchant bank with two de novo investment funds. Each of those funds’ investment returns significantly outperformed all relevant life sciences indices. Prior to founding Array, Ken was the Portfolio Manager of the Ariane Fund, an investment fund focused on the life sciences. He was responsible for the turnaround of Ariane by reorganizing the fund, raising all new investment monies, and generating double-digit returns each year.

Earlier in his career, Ken was also recruited to the U.S. Patent and Trademark Office (USPTO) by Commissioner Lehman to work on the Human Genome Policy steering body and to serve as a Biotechnology Patent Examiner. Ken’s input regarding the non-patentability of human genes was instrumental in developing constructive patent policy that has preserved incentives to discover and develop new biotechnologies and fueled research efforts ever since. He is also a designated patent agent.

Ken is a recipient of a dual B.S. in Molecular and Organismal Biology from the University of Kansas and a Ph.D. in Developmental Neurobiology from the University of Arizona.

Dr. Ted Witek has decades of experience in research, development, and leadership, as well as executive responsibilities as CSO and CEO, and has managed some of the sector’s largest strategic alliances. He is currently a Professor at the University of Toronto, directing the school’s Doctor of Public Health Program.

Previously, Ted served at Boehringer Ingelheim Pharmaceuticals for nearly 25 years, where he held various pharmacology and clinical research positions, including Director of Respiratory and Immunology Clinical Research, leading to his roles as President and CEO of Boehringer Ingelheim’s Canadian and Portuguese operations. He also led the Global Operating Team for Spiriva, serving as Co-Chair of the Global Alliance with Pfizer. Ted also was Chief Scientific Officer and Senior Vice President of Corporate Partnerships at Innoviva (formerly Theravance, Inc.).

Ted has also served on the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D), including as Chair of the Health Technology Assessment and Public Relations Committee. He is the author of more than 100 scientific papers, as well as several chapters and books.

Ted holds a Doctor of Public Health from Columbia University, a Master of Public Health from Yale University, and an MBA from Henley Management College in London.